ASMT gene expression correlates with cognitive impairment in patients with recurrent depressive disorder

Medical Science Monitor

Volumn 20, Issue , 2014, Pages 905-912

  Talarowska, Monika ^a   Szemraj, Janusz ^a   Zaja̧czkowska, Marlena ^a   Gałecki, Piotr ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

ASMT; Cognitive impairment; Depressive disorder

Indexed keywords

ACETYLSEROTONIN METHYLTRANSFERASE; RIBOSOME RNA; ASMT PROTEIN, HUMAN;

ACETYLSEROTONIN METHYLTRANSFERASE GENE; ADULT; AGED; ARTICLE; AUDITORY VERBAL LEARNING TEST; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GENE; GENE EXPRESSION; HAMILTON SCALE; HUMAN; LEARNING TEST; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MRNA EXPRESSION ASSAY; NEUROPSYCHOLOGICAL TEST; PROTEIN EXPRESSION; PSYCHOLOGIC TEST; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SPECTROPHOTOMETRY; STROOP TEST; VERBAL FLUENCY TEST; WORD LIST RECALL; COMPLICATION; DEPRESSION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; RECURRENT DISEASE; YOUNG ADULT;

ACETYLSEROTONIN O-METHYLTRANSFERASE; ADULT; AGED; COGNITION DISORDERS; DEPRESSIVE DISORDER; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; RECURRENCE; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84901953109     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/msm.890160     Document Type: Article

References (55)

1. Wittchen HU, Jacobi F, Rehm J et al: The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharm, 2011; 21: 655-79
2. Reynolds CF, Cuijpers P, Patel V et al: Early intervention to reduce the global health and economic burden of major depression in older adults. Annu Rev Public Health, 2012; 33: 123-35
3. Birchler-Pedross A, Frey S, Chellappa SL et al: Higher frontal EEG synchronization in young women with major depression: a marker for increased homeostatic sleep pressure? Sleep, 2011; 34(12): 1699-706
4. Etain B, Milhiet V, Bellivier F, Leboyer M: Genetics of circadian rhythms and mood spectrum disorders. Eur Neuropsychopharmacol. 2011; Suppl.4: 676-82
5. Talarowska M, Florkowski A, Gałecki P et al: Cognitive functions and depression. Psychiatr Pol, 2009; 43(1): 31-40
6. Williams RA, Hagerty BM, Cimprich B et al: Changes in directed attention and short-term memory in depression. J Psychiatr Res, 2000; 34(3): 227-38
7. Bremner JD, Vythilingam M, Vermetten E et al: Defcits in hippocampal and anterior cingulate functioning during verbal declarative memory encoding in midlife major depression. Am J Psychiatry, 2004; 161(4): 637-45
8. Sheline Y, Barch D, Garcia K et al: Cognitive function in late life depression: relationships to depression severity, cerebrovascular risk factors and processing speed. Biol Psychiatry, 2006; 60: 58-65
9. Joormann J, Gotlib IH: Updating the contents of working memory in depression: interference from irrelevant negative material. J Abnorm Psychol, 2008; 117; 1: 182-92
10. Kiosses D, Alexopoulos G: IADL Functions, Cognitive Defcits, and Severity of Depression: A Preliminary Study. Am J Geriatr Psychiatry, 2005; 13(3): 244-50
11. Watkins E, Brown R: Rumination and executive function in depression: an experimental study. J Neurol Neurosurg Psychiatry, 2002; 72(3): 400-3
12. Talarowska M, Florkowski A, Zboralski K et al: Auditory-verbal declarative and operating memory among patients sufering from depressive disorders - preliminary study. Adv Med Sci, 2010; 55(2): 317-27
13. Wetterberg L: The relationship between the pineal gland and the pituitary-adrenal axis in health, endocrine and psychiatric conditions. Psychoneuroendocrinology, 1983; 8(1): 75-80
14. Kripke DF, Nievergelt CM, Tranah GJ et al: Polymorphisms in melatonin synthesis pathways: possible infuences on depression. J Circadian Rhythms, 2011; 9: 8
15. Hansen MV, Madsen MT, Hageman I et al: The effect of MELatOnin on Depression, anxietY, cognitive function and sleep disturbances in patients with breast cancer. The MELODY trial: protocol for a randomised, placebo-controlled, double-blinded trial. 2012; 2(1): e000647
16. Dardente H, Wyse CA, Birnie MJ et al: A molecular switch for photoperiod responsiveness in mammals. Curr Biol, 2010; 20: 2193-98
17. Gross PK, Nourse R, Wasser TE: Ramelteon for insomnia symptoms in a community sample of adults with generalized anxiety disorder: an open label study. J Clin Sleep Med, 2009; 5(1): 28-33
18. Lustberg L, Reynolds CF: Depression and insomnia: questions of cause and effect. Sleep Med Rev, 2000; 4(3): 253-62
19. Pagan C, Botros HG, Poirier K et al: Mutation screening of ASMT, the last enzyme of the melatonin pathway, in a large sample of patients with intellectual disability. BMC Med Genet, 2011; 12: 17
20. Maes M, Yirmyia R, Noraberg J et al: The inflammatory & neurodegener-ative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis, 2009; 24(1): 27-53
21. Sharma AK, Mehta AK, Rathor N et al: Melatonin attenuates cognitive dysfunction and reduces neural oxidative stress induced by phosphamidon. Fundam Clin Pharmacol, 2013; 27(2): 146-51
22. Sharma M, Gupta YK: Effect of chronic treatment of melatonin on learning, memory and oxidative defciencies induced by intracerebroventricular streptozotocin in rats. Pharmacol Biochem Behav, 2001; 70(2-3): 325-31
23. Zawilska JB, Skene DJ, Arendt J: Physiology and pharmacology of melato-nin in relation to biological rhythms. Pharmacol Rep, 2009; 61(3): 383-410
24. Sugden D, Ceña V, Klein DC: Hydroxyindole O-methyltransferase. Hydroxyindole O-methyltransferase. Methods Enzymol, 1987; 142: 590-96
25. Reiter RJ, Tan DX, Terron MP et al: Melatonin and its metabolites: new fnd-ings regarding their production and their radical scavenging actions. Acta Biochim Pol, 2007; 54(1): 1-9
26. Botros HG, Legrand P, Pagan C et al: Crystal structure and functional mapping of human ASMT, the last enzyme of the melatonin synthesis pathway. J Pineal Res, 2013; 54(1): 46-57
27. Müller DJ, Schulze TG, Jahnes E et al: Association between a polymorphism in the pseudoautosomal X-linked gene SYBL1 and bipolar afective disorder. Am J Med Genet, 2002; 114(1): 74-78
28. ICD-10 Classifcation of Mental&Behavioural Disorders. Geneva: World Health Organization; 1993
29. Patten S: Performance of the Composite International Diagnostic Interview Short Form for major depression in community and clinical samples. Chronic Dis Can, 1997; 3: 18-24
30. Talarowska M, Gałecki P, Maes M et al: Total antioxidant status correlates with cognitive impairment in patients with recurrent depressive disorder. Neurochem Res, 2012; 37(8): 1761-67
31. Chomczyński P, Sacchi N: Single - step method of RNA isolation by acid guanidinium thiocyanatrphenol - chloroform extraction. Anal Biochem, 1987; 162: 156-59
32. Silva C, Tamura E, Macedo S et al: Melatonin inhibits nitric oxide production by microvascular endothelial cells In vivo and In vitro. Br J Pharmacol, 2007; 151: 195-205
33. Winer J, Jung CK, Shackel I et al: Development and validation of real-time quantitative rewers transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem, 1999; 270: 41-49
34. nd edition. Wiley-Bleckwell, 2003
35. Gałecki P, Szemraj J, Bartosz G et al: Single-nucleotide polymorphisms and mRNA expression for melatonin synthesis rate-limiting enzyme in recurrent depressive disorder. J Pineal Res, 2010; 48: 311-17
36. Etain B, Dumaine A, Bellivier F et al: Genetic and functional abnormalities of the melatonin biosynthesis pathway in patients with bipolar disorder. Hum Mol Genet. 2012;21(18): 4030-7.
37. Brusco LI, Marquez M, Cardinali DP: Melatonin treatment stabilizes chrono-biologic and cognitive symptoms in Alzheimer's disease. Neuro Endocrinol Lett, 2000; 21: 39-42
38. Kurtz AL, Kaufer DI: Dementia in Parkinson's disease. Curr Treat Options Neurol, 2011; 13(3): 242-54
39. Anderson G, Maes M: Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side efects. Metab Brain Dis, 2012; 27(2): 113-19
40. Jonsson L, Ljunggren E, Bremer A et al: Mutation screening of melato-nin-related genes in patients with autism spectrum disorders. BMC Med Genomics, 2010; 3: 10
41. Chaste P, Clement N, Botros HG et al: Genetic variations of the melatonin pathway in patients with attention-defcit and hyperactivity disorders. J Pineal Res, 2011; 51(4): 394-99
42. Harrison NA, Brydon L, Walker C et al: Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry, 2009; 66(5): 407-14
43. Herrera F, Martin V, García-Santos G et al: Melatonin prevents glutamate-induced oxytosis in the HT22 mouse hippocampal cell line through an an-tioxidant efect specifcally targeting mitochondria. J Neurochem, 2007; 100(3): 736-46
44. Ramirez-Rodriguez G, Ortiz-Lopez L, Dominguez-Alonso A et al: Chronic treatment with melatonin stimulates dendrite maturation and complexity in adult hippocampal neurogenesis of mice. J Pineal Res, 2011; 50: 29-37
45. Monje FJ, Cabatic M, Divisch I et al: Constant darkness induces IL-6-dependent depression-like behavior through the NF-kB signaling pathway. 2011; 31(25): 9075-83
46. Alesci S, Martinez PE, Kelkar S et al: Major depression is associated with signifcant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. J Clin Endocrinol Metab, 2005; 90(5): 2522-30
47. Srinivasan V, Pandi-Perumal SR, Trakht I et al: Pathophysiology of depression: role of sleep and the melatonergic system. Psychiatry Res, 2009; 165(3): 201-14
48. Ozcan M, Yilmaz B, Carpenter DO: Efects of melatonin on synaptic transmission and long-term potentiation in two areas of mouse hippocampus. Brain Res, 2006; 1111(1): 90-94
49. Nedzvetsky VS, Nerush PA, Kirichenko SV: Effect of Melatonin on Cognitive Ability of Rats and Expression of NCAM in Brain Structures in Streptozotocin-Induced Diabetes. Neurophysiology, 2003; 35(6)
50. Laborie S: Efect of bright light and melatonin on cognitive and non-cognitive function. Cah Année Gérontol, 2010; 2: 194-98
51. Baydas G, Nedzvetsky VS, Nerush PA et al: A novel role for melatonin: regulation of the expression of cell adhesion molecules in the rat hippocampus and cortex. Neurosci Lett, 2002; 326(2): 109-12
52. Ramírez-Rodríguez G, Vega-Rivera NM, Benítez-King G et al: Melatonin supplementation delays the decline of adult hippocampal neurogenesis during normal aging of mice. Neurosci Lett, 2012; 530(1): 53-58
53. Rothman SM, Mattson MP: Sleep Disturbances in Alzheimer's and Parkinson's Diseases. Neuromol Med, 2012; 14: 194-204
54. Olcese JM, Cao C, Mori T et al: Protection against cognitive defcits and markers of neurodegeneration by long-term oral administration of mela-tonin in a transgenic model of Alzheimer disease. J Pineal Res, 2009; 47: 82-96
55. Baydas G, Ozer M, Yasar A et al: Melatonin improves learning and memory performances impaired by hyperhomocysteinemia in rats. Brain Res, 2005; 1046(1-2): 187-89